Evelo Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Evelo Biosciences, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q3 2023.
  • Evelo Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2023 was $2.48M, a 28.5% decline year-over-year.
  • Evelo Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2023 was $11.2M, a 30.6% decline year-over-year.
  • Evelo Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $15.2M, a 4.34% decline from 2021.
  • Evelo Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $15.8M, a 87.1% increase from 2020.
  • Evelo Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $8.47M, a 3.71% increase from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $11.2M $2.48M -$987K -28.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $12.2M $2.37M -$1.63M -40.9% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $13.8M $2.91M -$1.37M -32% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $15.2M $3.42M -$948K -21.7% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-16
Q3 2022 $16.1M $3.46M -$978K -22% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $17.1M $4M +$227K +6.02% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $16.9M $4.28M +$1.01M +31% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $15.8M $4.37M +$2.09B Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$2.08B $4.44M +$2.4M +117% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$2.08B $3.77M -$2.09B -99.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $9.78M $3.26M +$1.31M +67% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $8.47M -$2.09B -$2.09B -103749% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 $2.1B $2.05M -$17K -0.82% Jul 1, 2020 Sep 30, 2020 10-Q/A 2021-10-29
Q2 2020 $2.1B $2.09B* +$2.09B +97933% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $8.17M $1.96M +$2K +0.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q4 2019 $8.17M $2.02M +$450K +28.8% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 $7.72M $2.06M +$467K +29.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-30
Q2 2019 $7.25M $2.14M -$112K -4.98% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-31
Q1 2019 $7.36M $1.95M +$1.3M +200% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $6.06M $1.57M +$929K +146% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-14
Q3 2018 $5.13M $1.6M +$1.16M +267% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $3.97M $2.25M +$1.98M +738% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $1.99M $652K +$449K +221% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-03
Q4 2017 $1.54M $636K Oct 1, 2017 Dec 31, 2017 10-K 2020-02-14
Q3 2017 $435K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-02
Q2 2017 $268K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $203K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.